Woodline Partners LP filed Amendment No. 2 to its Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 5,455,694 shares of SAB Biotherapeutics, Inc. common stock as of September 30, 2026.
Key Highlights
- Aggregate beneficial ownership: Woodline Partners LP reported beneficial ownership of 5,455,694 shares of SAB Biotherapeutics common stock.
- Ownership percentage: The reported stake represents 5.7% of the class, calculated based on 90,986,368 shares outstanding as of August 3, 2026.
- Direct common stock held: 1,180,694 shares of common stock are held directly by Woodline Master Fund LP.
- Enrollment Warrants component: 2,850,000 shares are issuable upon conversion of 28,500 shares of Series B Preferred Stock underlying 28,500 Enrollment Warrants.
- Data Release Warrants component: 1,425,000 shares are issuable upon conversion of 14,250 shares of Series B Preferred Stock underlying 14,250 Data Release Warrants.
- Voting and dispositive power: Woodline Partners reported sole voting power and sole dispositive power over all 5,455,694 shares, with zero shared voting or dispositive power.
Woodline Partners Discloses Position Structure in SAB Biotherapeutics
According to the filing, Woodline Partners LP is a Delaware limited partnership that acts as investment adviser to Woodline Master Fund LP. The position reported in this amendment covers common stock of SAB Biotherapeutics, Inc. (NASDAQ:SABS), a biotherapeutic company headquartered at 777 W 41st St, Suite 401, Miami Beach, Florida 33140. The filing notes that Woodline Partners' principal business office is located at 4 Embarcadero Center, Suite 3450, San Francisco, CA 94111.
The filing discloses that the aggregate beneficial ownership of 5,455,694 shares consists of three components: 1,180,694 shares of common stock held directly, 2,850,000 shares issuable upon conversion of Series B Preferred Stock underlying Enrollment Warrants, and 1,425,000 shares issuable upon conversion of Series B Preferred Stock underlying Data Release Warrants. The percentage calculation assumes the conversion of the Series B Preferred Stock issuable upon exercise of both warrant types, and is based on the share count reported in the company's quarterly report for the period ended June 30, 2026, filed on August 6, 2026.
The filing states that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The statement was signed by Erin Mullen, General Counsel and Chief Compliance Officer of Woodline Partners LP, on November 16, 2026. The filing further notes that Woodline Master Fund LP holds the right to receive dividends from, or proceeds from the sale of, the shares reported.
What Was Disclosed
Woodline Partners LP filed Amendment No. 2 to its Schedule 13G disclosing 5,455,694 shares beneficially owned in SAB Biotherapeutics, Inc., representing 5.7% of the class as of the September 30, 2026 event date, with all voting and dispositive power held solely by the reporting person.





Please wait processing your request...